Logo

DAWN

Day One Biopharmaceuticals, Inc.

DAWN

Day One Biopharmaceuticals, Inc. • NASDAQ
$9.49 ▲ 0.85% (+0.08)
Market Cap $974.39 M
52w High $14.46
52w Low $5.63
Dividend Yield 0%
P/E -6.24
Volume 653.74K
Outstanding Shares 102.68M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $39.795M ▲ $59.566M ▼ $-19.726M ▲ -49.569% ▲ $-0.19 ▲ $-18.787M ▲
Q2-2025 $33.908M ▲ $65.117M ▼ $-30.322M ▲ -89.424% ▲ $-0.29 ▲ $-29.358M ▲
Q1-2025 $30.761M ▲ $68.944M ▼ $-35.996M ▲ -117.018% ▲ $-0.35 ▲ $-35.102M ▲
Q4-2024 $29.208M ▼ $91.558M ▲ $-65.714M ▼ -224.986% ▼ $-0.7 ▼ $-58.481M ▼
Q3-2024 $93.761M $62.535M $37.037M 39.501% $0.38 $36.901M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $451.58M ▼ $513.78M ▼ $62.912M ▲ $450.868M ▼
Q2-2025 $453.103M ▼ $519.037M ▼ $58.203M ▲ $460.834M ▼
Q1-2025 $473.02M ▼ $534.356M ▼ $54.844M ▼ $479.512M ▼
Q4-2024 $531.72M ▼ $582.788M ▼ $80.037M ▲ $502.751M ▼
Q3-2024 $558.383M $600.807M $45.344M $555.463M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-19.726M ▲ $-5.805M ▲ $13.46M ▼ $0 ▼ $7.655M ▲ $-5.805M ▲
Q2-2025 $-30.322M ▲ $-24.806M ▲ $26.322M ▲ $748K ▲ $2.264M ▲ $-21.309M ▲
Q1-2025 $-35.996M ▲ $-58.997M ▼ $-32.613M ▲ $0 ▼ $-91.61M ▲ $-62.814M ▼
Q4-2024 $-65.714M ▼ $-30.008M ▼ $-269.64M ▼ $1.851M ▼ $-297.797M ▼ $-31.427M ▼
Q3-2024 $37.037M $50.753M $-67.699M $200.095M $183.149M $-4.971M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
License
License
 $0 ▲$0 ▲$0 ▲$0 ▲
Product
Product
 $30.00M ▲$30.00M ▲$30.00M ▲$40.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Day One is still very much in the investment phase: expenses are high while revenue has only just begun to appear. For several years the company generated virtually no sales as it advanced its pipeline; losses widened as it scaled up research and the organization around its lead drug. In the most recent year, a modest level of product revenue shows that commercialization has started, but it is still far from covering operating costs. Net losses remain substantial, though they appear to have stopped worsening and have slightly improved versus the prior year. Overall, the income statement reflects an early commercial biotech reliant on future growth, not current profitability.

Balance Sheet

Balance Sheet The balance sheet shows a company funded mainly by equity, with no financial debt, which gives it flexibility and avoids interest burden. Total assets have grown meaningfully over time as Day One raised capital and built its cash and investment balances after going public. Cash is a significant portion of assets, though it has moved up and down with fundraising and spending on trials and launch preparation. Shareholders’ equity was negative before and shortly after the IPO but has turned clearly positive in recent years, indicating the balance sheet has been repaired and strengthened. The key watchpoint is how long the current capital base can support ongoing losses before additional funding is required.

Cash Flow

Cash Flow Cash flow is dominated by outflows from operations, reflecting heavy spending on clinical development, regulatory work, and now commercialization. Operating cash burn has increased as the company progressed from early-stage research to multiple trials and a product launch, and free cash flow is similarly negative because Day One spends little on physical assets. Capital expenditure needs are minimal, so almost all cash use is tied directly to growth and R&D rather than factories or equipment. This pattern is typical for a development‑stage biotech, but it means the company remains dependent on its cash reserves and capital markets until its products generate much larger and more stable revenues. Investors will want to monitor whether cash burn begins to level off or improve as commercialization ramps.

Competitive Edge

Competitive Edge Day One has carved out a specialized position in pediatric oncology, targeting a genetically defined slice of brain cancer where treatment options have been limited. Its lead drug, OJEMDA, has first‑mover status for a specific subgroup of pediatric low‑grade glioma, supported by strong clinical data and regulatory designations that grant market exclusivity and other incentives. The narrow but critical focus on children’s cancers helps build deep relationships with pediatric oncologists and treatment centers, creating a reputational edge that is not trivial for generalist oncology players to replicate. At the same time, the company operates in a space where large pharmaceutical firms are active in the same signaling pathways, so competitive pressure over time is a real risk. Day One’s ability to expand indications, combine therapies, and maintain clinical differentiation will be central to sustaining its position.

Innovation and R&D

Innovation and R&D Innovation is the core of Day One’s strategy. Rather than discovering everything in‑house, it uses a “search and development” model, in‑licensing promising assets that are already partway through development and then pushing them through pediatric and genetically defined cancer indications. OJEMDA, designed to cross the blood‑brain barrier and hit both classic BRAF mutations and BRAF fusions, is a good example of this targeted and patient‑centric approach, including its convenient once‑weekly oral dosing. Beyond OJEMDA, the company is working on combination strategies in the same pathway and has added a novel antibody‑drug conjugate program that could broaden its reach into other solid tumors. R&D spending is substantial, but it is being directed into a focused pipeline with clear clinical milestones, making execution on trials and timely data readouts the key variables to watch.

Summary

Day One Biopharmaceuticals is transitioning from a pure development story to an early commercial oncology company. Financially, it remains loss‑making with meaningful cash burn, but it has a debt‑free balance sheet and a strengthened equity base that provide room to pursue its strategy. The first signs of revenue from OJEMDA validate years of investment, yet current sales are still small relative to the cost structure, so the trajectory of uptake and label expansion will be important. Strategically, the firm benefits from a first‑in‑class pediatric brain cancer therapy, regulatory advantages, and a focused network in pediatric oncology, all of which support a recognizable niche. Future prospects hinge on successful commercialization of OJEMDA, positive outcomes from follow‑on trials and pipeline programs, and disciplined management of cash as the company balances growth ambitions with funding needs.

NEWS

November 24, 2025 · 8:00 AM UTC

Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting

Read more

November 18, 2025 · 8:30 AM UTC

Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference

Read more

November 13, 2025 · 6:00 AM UTC

Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases

Read more

November 10, 2025 · 7:00 AM UTC

Day One Announces New OJEMDA™ (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting

Read more

November 4, 2025 · 4:00 PM UTC

Day One Reports Third Quarter 2025 Financial Results and Corporate Progress

Read more